These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 22188080)

  • 1. Cerebral venous thrombosis in an individual with multiple myeloma treated with lenalidomide.
    Eudo C; Petit A; Mondon K; Rippault H; Dardaine V; Constans T; Hommet C; Cottier JP
    J Am Geriatr Soc; 2011 Dec; 59(12):2371-2. PubMed ID: 22188080
    [No Abstract]   [Full Text] [Related]  

  • 2. Lenalidomide and venous thrombosis in multiple myeloma.
    Rajkumar SV; Blood E
    N Engl J Med; 2006 May; 354(19):2079-80. PubMed ID: 16696148
    [No Abstract]   [Full Text] [Related]  

  • 3. Lenalidomide and venous thrombosis in multiple myeloma.
    Knight R; DeLap RJ; Zeldis JB
    N Engl J Med; 2006 May; 354(19):2079-80. PubMed ID: 16687729
    [No Abstract]   [Full Text] [Related]  

  • 4. Recombinant human erythropoietin and the risk of thrombosis in patients receiving thalidomide for multiple myeloma.
    Galli M; Elice F; Crippa C; Comotti B; Rodeghiero F; Barbui T
    Haematologica; 2004 Sep; 89(9):1141-2. PubMed ID: 15377478
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anticoagulation regimens for thalidomide and lenalidomide.
    Zangari M
    Clin Adv Hematol Oncol; 2006 Sep; 4(9):658-9. PubMed ID: 17099621
    [No Abstract]   [Full Text] [Related]  

  • 6. Risk of thrombosis with lenalidomide and its prevention with aspirin.
    Hirsh J
    Chest; 2007 Jan; 131(1):275-7. PubMed ID: 17218586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How to prevent deep vein thrombosis in myeloma patients receiving thalidomide or lenalidomide.
    Kastritis E; Dimopoulos M
    Leuk Lymphoma; 2007 Dec; 48(12):2295-7. PubMed ID: 18066998
    [No Abstract]   [Full Text] [Related]  

  • 8. Deep venous thrombosis and thalidomide therapy for multiple myeloma.
    Osman K; Comenzo R; Rajkumar SV
    N Engl J Med; 2001 Jun; 344(25):1951-2. PubMed ID: 11419443
    [No Abstract]   [Full Text] [Related]  

  • 9. Neutrophilic dermatosis complicating lenalidomide therapy.
    Thieu KP; Rosenbach M; Xu X; Kist JM
    J Am Acad Dermatol; 2009 Oct; 61(4):709-10. PubMed ID: 19577327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and genetic factors associated with venous thromboembolism in myeloma patients treated with lenalidomide-based regimens.
    Bagratuni T; Kastritis E; Politou M; Roussou M; Kostouros E; Gavriatopoulou M; Eleutherakis-Papaiakovou E; Kanelias N; Terpos E; Dimopoulos MA
    Am J Hematol; 2013 Sep; 88(9):765-70. PubMed ID: 23757261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Arterial thrombosis with immunomodulatory derivatives in the treatment of multiple myeloma: a single-center case series and review of the literature.
    Martin MG; Vij R
    Clin Lymphoma Myeloma; 2009 Aug; 9(4):320-3. PubMed ID: 19717384
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A practical guide to achieving and maintaining the best response to lenalidomide in multiple myeloma: roundtable proceedings.
    Stadtmauer EA; Lonial S; Vesole DH; Abonour R; Alsina M; Badros A; Comenzo R; Durie B; Giralt S; Hussein M; Jakubowiak A; Mehta J; Niesvizky R; Orlowski R; Siegel D; Singhal S; Vescio R; Wang M; Zangari M; Munshi NC
    Clin Adv Hematol Oncol; 2007 Oct; 5(10 Suppl 15):7-19, quiz 21-2. PubMed ID: 18000495
    [No Abstract]   [Full Text] [Related]  

  • 13. Arterial and venous thrombotic complications with thalidomide in multiple myeloma.
    Alkindi S; Dennison D; Pathare A
    Arch Med Res; 2008 Feb; 39(2):257-8. PubMed ID: 18164975
    [No Abstract]   [Full Text] [Related]  

  • 14. Lenalidomide and its role in the management of multiple myeloma.
    Falco P; Cavallo F; Larocca A; Liberati AM; Musto P; Boccadoro M; Palumbo A
    Expert Rev Anticancer Ther; 2008 Jun; 8(6):865-74. PubMed ID: 18533796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of treatment-related adverse events in patients with multiple myeloma.
    Mateos MV
    Cancer Treat Rev; 2010 May; 36 Suppl 2():S24-32. PubMed ID: 20472185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lenalidomide, a thalidomide derivative, shows promise in various applications.
    Oestreicher P
    ONS Connect; 2007 Aug; 22(8):22-3. PubMed ID: 17824579
    [No Abstract]   [Full Text] [Related]  

  • 17. A case of severe aplastic anemia secondary to treatment with lenalidomide for multiple myeloma.
    Dasanu CA; Alexandrescu DT
    Eur J Haematol; 2009 Mar; 82(3):231-4. PubMed ID: 19018868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lenalidomide: new drug. Myeloma: many questions remain unanswered.
    Prescrire Int; 2008 Dec; 17(98):230-2. PubMed ID: 19422142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thalidomide therapy and deep venous thrombosis in multiple myeloma.
    Rajkumar SV
    Mayo Clin Proc; 2005 Dec; 80(12):1549-51. PubMed ID: 16350272
    [No Abstract]   [Full Text] [Related]  

  • 20. The clinical utility of lenalidomide in multiple myeloma and myelodysplastic syndromes.
    Bonkowski J; Vermeulen LC; Kolesar JM
    J Oncol Pharm Pract; 2010 Dec; 16(4):223-32. PubMed ID: 19910392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.